These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Klein B; Seckinger A; Moehler T; Hose D Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680 [TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis. Liu YC; Margolskee E; Allan JN; Mathew S; Bhavsar E; Casano J; Orazi A; Furman RR; Geyer JT Mod Pathol; 2020 Mar; 33(3):344-353. PubMed ID: 31477813 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bone marrow histology in multiple myeloma. Subramanian R; Basu D; Dutta TK Indian J Cancer; 2009; 46(1):40-5. PubMed ID: 19282565 [TBL] [Abstract][Full Text] [Related]
8. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Carballo-Zarate AA; Medeiros LJ; Fang L; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Hao S; Shen Q; Orlowski RZ; Lin P; Lu X Mod Pathol; 2017 Jun; 30(6):843-853. PubMed ID: 28281554 [TBL] [Abstract][Full Text] [Related]
9. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804 [TBL] [Abstract][Full Text] [Related]
10. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization]. An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360 [TBL] [Abstract][Full Text] [Related]
11. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712 [TBL] [Abstract][Full Text] [Related]
12. Natural history of multiple myeloma with de novo del(17p). Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679 [TBL] [Abstract][Full Text] [Related]
13. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394 [TBL] [Abstract][Full Text] [Related]
14. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates. Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of plasma cell morphology in multiple myeloma. Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725 [TBL] [Abstract][Full Text] [Related]
16. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347 [TBL] [Abstract][Full Text] [Related]
17. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124 [TBL] [Abstract][Full Text] [Related]
18. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439 [TBL] [Abstract][Full Text] [Related]